Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
The combination of anlotinib and TQB2450 is effective and tolerable in patients with ASPS. TLS may serve as a prognostic biomarker, meriting further investigation.
Authors
- Zhichao Tan (ORCID: https://orcid.org/0000-0001-9074-9047)
- Yan Wu (ORCID: https://orcid.org/0000-0002-2355-0887)
- Ruifeng Xue (ORCID: https://orcid.org/0000-0002-1185-3506)
- Wei Guo (ORCID: https://orcid.org/0000-0003-2471-5767)
- Lu Zhang (ORCID: https://orcid.org/0009-0008-7112-9342)
- Ling Jia (ORCID: https://orcid.org/0009-0006-7964-2517)
- Tian Gao (ORCID: https://orcid.org/0000-0001-6843-2959)
- Zhengfu Fan (ORCID: https://orcid.org/0000-0002-3616-1848)
- Xinyu Wang (ORCID: https://orcid.org/0009-0007-0789-9660)
- Jiayong Liu (ORCID: https://orcid.org/0000-0002-4798-5404)
- Chujie Bai (ORCID: https://orcid.org/0000-0003-1072-5219)
- Shu Li (ORCID: https://orcid.org/0000-0001-8409-5390)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University People's Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2444
- Citations
- 10
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- Wu Jieping Medical Foundation